What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
Treatment with dupilumab led to significant improvements in lung function by 16 weeks and up to 24 weeks in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma plus clinical features of COPD.
In patients with idiopathic pulmonary fibrosis, treatment with pirfenidone was associated with a lower risk of mortality and acute respiratory-related hospitalizations than treatment with nintedanib.
Treatment with LIQ861, an inhaled dry-powder form of treprostinil, was associated with significant improvements in several clinical and quality of life measures in patients with pulmonary arterial hypertension.
Treatment with steroids within a 48-hour period after intubation in the intensive care unit was not associated with the development of acute respiratory distress syndrome.
Nebulized ensifentrine, when added to tiotropium, produced clinically meaningful and significant improvements in lung function and quality of life in patients with COPD.
Continuous positive airway pressure therapy for 6 months offers patients with obstructive sleep apnea a greater chance of reversing metabolic syndrome.
Patients with COPD who received a metered dose inhaler containing budesonide, glycopyrrolate, and formoterol fumarate showed lung function improvements through 52 weeks.
Subclinical bacteria in the home environment likely influence the airway microbiome and contribute to poor asthma control in patients with refractory asthma.
Patients with severe eosinophilic asthma who received benralizumab experienced significant improvements in several health-related quality of life measures.